17th week of 2015 patent applcation highlights part 38 |
Patent application number | Title | Published |
20150110691 | LIQUID FUEL FOR ISOLATING WASTE MATERIAL AND STORING ENERGY - Techniques, systems, apparatus, and materials are disclosed for generating multi-purpose liquid fuel for isolating contaminants and storing energy. In one aspect, a method of producing a liquid fuel includes forming a gaseous fuel (e.g., by dissociating biomass waste using waste heat recovered from an external heat source). Carbon dioxide emitted from an industrial process can be harvested and reacted with the gaseous fuel to generate the liquid fuel. A hazardous contaminant can be dissolved in the liquid fuel, with the liquid fuel operating as a solvent or continuous phase for a solution or colloid that isolates the hazardous contaminant from the environment. The hazardous contaminant can include at least one of a carbon donor and a hydrogen donor. | 2015-04-23 |
20150110692 | METHOD FOR PRODUCING HIGH-PURITY MANGANESE SULFATE MONOHYDRATE AND HIGH-PURITY MANGANESE SULFATE MONOHYDRATE PRODUCED BY THE METHOD - A method for producing high-purity manganese sulfate monohydrate from a low-grade composition includes acquiring a primary leached manganese solution by adding sulfuric acid and a reductant to a low-grade manganese-containing composition and leaching manganese therefrom; acquiring a secondary leached manganese solution from which primary impurities have been eliminated by adding calcium hydroxide to the primary leached manganese solution; acquiring a tertiary leached manganese solution from which secondary impurities have been eliminated by adding sulfides to the secondary leached manganese solution; acquiring manganese oxide from precipitating manganese by using sodium hydroxide in the tertiary leached manganese solution so as to control the pH thereof; adding sulfuric acid to the manganese oxide and redissolving; and drying the redissolved manganese oxide and acquiring high-purity manganese sulfate monohydrate. Thus the present invention allows production of high-purity manganese sulfate monohydrate from a low-grade manganese-containing composition, for use as material for a secondary battery. | 2015-04-23 |
20150110693 | HIGH-EFFICIENCY CATALYTIC CONVERTERS FOR TREATING EXHAUST GASES - Several embodiments of high-efficiency catalytic converters and associated systems and methods are disclosed. In one embodiment, a catalytic converter for treating a flow of exhaust gas comprising a reaction chamber, a heating enclosure enclosing at least a portion of the reaction chamber, and an optional coolant channel encasing the heating enclosure. The reaction chamber can have a first end section through which the exhaust gas flows into the reaction chamber and a second end section from which the exhaust gas exits the reaction chamber. The heating enclosure is configured to contain heated gas along the exterior of the reaction chamber, and the optional coolant channel is configured to contain a flow of coolant around the heating enclosure. The catalytic converter can further include a catalytic element in the reaction chamber. | 2015-04-23 |
20150110694 | METHODS AND SYSTEMS FOR CARRYING OUT A pH-INFLUENCED CHEMICAL AND/OR BIOLOGICAL REACTION - The present invention generally relates to methods and systems for carrying out a pH-influenced chemical and/or biological reaction. In some embodiments, the pH-influenced reaction involves the conversion of CO | 2015-04-23 |
20150110695 | AQUEOUS ALKANOLAMINE COMPOSITION AND PROCESS FOR THE REMOVAL OF ACID GASES FROM GASEOUS MIXTURES - The present invention relates to an aqueous alkanolamine solution for the removal of hydrogen sulfide from gaseous mixtures. The aqueous alkanolamine solution comprises (i) an amino compound with the formula: R | 2015-04-23 |
20150110696 | Reversible Sorbent for Warm CO2 Capture by Pressure Swing Adsorption - Sorbent for reversible warm CO | 2015-04-23 |
20150110697 | METHYL IODIDE ADSORBER, USE THEREOF AND METHOD FOR THE ADSORPTION OF METHYL IODIDE - A methyl iodide adsorber, comprising a zeolite containing at least one iodide-adsorbing metal or a compound thereof, wherein the zeolite is a hydrophobic zeolite. Also, a use of the adsorber and a method for the adsorption of methyl iodide. | 2015-04-23 |
20150110698 | Process for Sulfur Dioxide, Hydrochloric Acid and Mercury Mediation - Dry processes, apparatus, compositions and systems are provided for reducing emissions of sulfur oxides, and sulfur dioxide in particular, and/or HCl and/or Hg in a process employing a combination of a lime-based sorbent, in particular hydrated lime and/or dolomitic hydrated lime, and a sorbent doping agent administered to achieve coverage of a three-dimensional cross section of a passage carrying SO | 2015-04-23 |
20150110699 | APPARATUS AND METHOD FOR MANUFACTURING SiO - Disclosed is an apparatus and method for manufacturing SiO, which may lower a manufacturing cost of SiO by collecting SiO continuously. The apparatus for manufacturing SiO includes a reaction unit configured to receive a SiO-making material and bring the received material into reaction by heating to generate a SiO gas; and a collecting unit configured to maintain an internal temperature lower than an internal temperature of the reaction unit, the collecting unit including a rotating member in an inner space thereof, wherein the collecting unit collects a SiO deposit by introducing the SiO gas generated by the reaction unit through an inlet formed at least at one side thereof and allowing the introduced SiO gas to be deposited to a surface of the rotating member. | 2015-04-23 |
20150110700 | Process for preparing precipitated silica using a mixer or extruder - A process for preparing precipitated silica comprising a reaction of a silicate with an acidifying agent to obtain a suspension of precipitated silica (S1), followed by a separation step to obtain a cake, a disintegration step of said cake to obtain a suspension of precipitated silica (S2), and a drying step of this suspension, wherein the disintegration step is performed by mixing using a twin-screw mixer or by extrusion. | 2015-04-23 |
20150110701 | BIOGENIC SILICA AS A RAW MATERIAL TO CREATE HIGH PURITY SILICON - A low cost process is provided for creating high purity silicon from agricultural waste, particularly rice hull ash. The process uses a series of chemical and thermal steps to yield high purity silica while using less energy and more efficient chemical processes. The high purity silicon features fewer impurities that negatively affect the use of high purity for PV cells and reduces capital and operating costs of processes to yield ultra-pure silicon. | 2015-04-23 |
20150110702 | PRODUCTION OF POLYCRYSTALLINE SILICON IN SUBSTANTIALLY CLOSED-LOOP PROCESSES THAT INVOLVE DISPROPORTIONATION OPERTIONS - Production of polycrystalline silicon in substantially closed-loop processes and systems is disclosed. The processes and systems generally involve disproportionation of trichlorosilane to produce silane or dichlorosilane and thermal decomposition of silane or dichlorosilane to produce polycrystalline silicon. | 2015-04-23 |
20150110703 | REACTOR WITH INDUCTION HEATER - A method for producing usable product in a reactor including introducing a viscous mixture including usable product and unconverted reactant into a chamber of a housing through an inlet, wherein the mixture has a temperature greater than ambient temperature when introduced into the chamber; heating the viscous mixture in the chamber using at least one of an induction heater, an exothermic reaction, a microwave heater, a radio frequency heater, an electrical resistance heater, a laser heater, a plasma heater, and a heated fluid; converting at least a portion of the unconverted reactant to usable product, wherein at least a portion of the usable product is produced in the viscous mixture; and transferring the viscous mixture including usable product from the housing through an outlet. | 2015-04-23 |
20150110704 | Method for Preparing Carbon Nanotube Fibers with Improved Spinning Properties Using Surfactant - The present invention provides a method for preparing carbon nanotube fibers with improved spinning properties using a surfactant and carbon nanotube fibers prepared by the method. According to the method for preparing carbon nanotube fibers of the present invention, the addition of a surfactant during the preparation of carbon nanotubes interrupts and delays the agglomeration of catalyst particles, which reduces the size of the catalyst particles and uniformly disperses the catalyst particles that play a key role in the formation of carbon nanotube fibers, thus increasing the strength and conductivity of carbon nanotube fibers and improving the spinning properties. While convention methods prepare carbon nanotube fibers by injecting a catalytic material for the synthesis of carbon nanotubes in a high-pressure supercritical state to be uniformly dispersed, the present invention uses a dispersant and thus does not require the injection in a high-pressure supercritical state. | 2015-04-23 |
20150110705 | CARBON FIBER PRECURSOR ACRYLIC FIBER BUNDLE, METHOD FOR THERMALLY OXIDIZING PART THEREOF, THERMAL OXIDATION OVEN, AND PROCESS FOR PRODUCING CARBON FIBER BUNDLE - Provided is a carbon-fiber-precursor acrylic fiber bundle which can smoothly pass through a flame-resistance impartation step and a carbonization step. The carbon-fiber-precursor acrylic fiber bundle has a high-density part as a portion thereof, wherein the high-density part satisfies the following requirements (A) and (B). Requirement A: The high-density part has a maximum fiber density ρ | 2015-04-23 |
20150110706 | Hydrogen Surface-Treated Graphene, Formation Method Thereof and Electronic Device Comprising The Same - The present invention relates to hydrogen surface-treated graphene, a formation method thereof, and an electronic device including the same. The graphene according to one exemplary embodiment of the present invention can be useful in preparing hydrogen surface-treated graphene having a band gap using simple methods through indirect hydrogen plasma treatment. Also, the graphene according to one exemplary embodiment of the present invention can be useful in forming two regions having different band gaps through the indirect hydrogen plasma treatment, and thus can be useful in reducing the processing time and the processing cost since the graphene is directly applicable to electronic devices such as transistors, and touch panels. | 2015-04-23 |
20150110707 | PROCESS FOR MAKING CHEMICALLY ACTIVATED CARBON - A method for making activated carbon includes heating a mixture of a carbon precursor or a carbonized precursor and a chemical activating agent in a furnace. The furnace includes an internal surface either formed from or lined with a corrosion resistant material such as high purity silicon carbide or silicon nitride. | 2015-04-23 |
20150110708 | Integrated Process for the Production of Hydrogen and Water - Process for producing a hydrogen-containing product and one or more liquid water products using catalytic steam-hydrocarbon reforming. In the process, a portion of the make-up water is heated by the reformate and another portion of the make-up water is heated by the combustion product gas prior to introducing the make-up water to a deaerator. Water in the combustion product gas is condensed to form a liquid water product. The process may be integrated with a thermal water desalination process. | 2015-04-23 |
20150110709 | METHOD FOR PRODUCING NANOPARTICLES - A method for producing a nanoparticle to separate a diketopyrrolopyrrole pigment includes separating an α-type diketopyrrolopyrrole pigment nanoparticle having high crystallinity by carrying out separation of the diketopyrrolopyrrole pigment and crystal type transformation to the α-type with substantially a single step. The α-type diketopyrrolopyrrole pigment nanoparticle is separated by mixing a diketopyrrolopyrrole pigment solution having the diketopyrrolopyrrole pigment dissolved in a solvent and an alcohol solvent containing an alcohol compound solvent in a thin film fluid formed between at least two processing surfaces | 2015-04-23 |
20150110710 | PROCESS FOR PREPARING POWDER WITH ENHANCED BULK HANDLING PROPERTY - The present invention relates to a process for manufacturing low-dusting, smoothly-discharging, easily dispersible, powders such as pigmentary titanium dioxide that resist compaction, aging, lumping, and/or caking. Particularly, the present invention relates to a process for treating powders such as pigmentary titanium dioxide with ammonia or a similarly basic substance prior to or during agglomeration to produce a powder with improved bulk handling properties. | 2015-04-23 |
20150110711 | PROCESS FOR THE DIRECT SYNTHESIS OF CU-SAPO-34 - Process for the direct synthesis of Cu-SAPO-34 comprising at least the following steps: preparation of a mixture containing water, at least one silicon source, at least one Al source, at least one P source, at least one Cu source, at least one OSDA1 (where OSDA1 is any polyamine), and at least one OSDA2 (where OSDA2 is any organic molecule capable of directing the synthesis of the SAPO-34); and where the final synthesis mixture has the next molar composition: a Si:0.5 Al:b P:c Cu:d OSDA1:e OSDA2:f H20 wherein a is in the range from 0.01 to 0.3; wherein b is in the range from 0.2 to 0.49; wherein c is in the range from 0.001 to 0.6; wherein d is in the range from 0.001 to 0.6; wherein e is in the range from 0.001 to 2; wherein f is in the range from 1 to 200; hydrothermal treatment of the mixture at 80-200° C. until formation of the crystalline material, and recovery of the crystal-line material. | 2015-04-23 |
20150110712 | CRYSTALLINE MOLECULAR SIEVES AND RELATED STRUCTURE-DIRECTING AGENTS, METHODS AND SYSTEMS - A composition and method for preparing molecular sieves having a STW framework structure are described wherein a structure directing agent comprising quaternary cation 1,2,3,4,5-pentamethyl-1H-imidazol-3-ium is contacted with a source of an oxide of a first tetravalent element with or without a source of an oxide of another tetravalent elements and/or a source of a trivalent element in a molar ratio of tetravalent element: trivalent element 100:1 and greater. | 2015-04-23 |
20150110713 | METHOD AND COMPOSITION FOR TREATING CANCER - A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species. | 2015-04-23 |
20150110714 | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand - The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent. | 2015-04-23 |
20150110715 | Double-Labeled Probe for Molecular Imaging and Use Thereof - The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof. | 2015-04-23 |
20150110716 | METHODS OF USING SPECT/CT ANALYSIS FOR STAGING CANCER - A method of evaluating a subject suspected of harboring a prostrate tumor includes administering to the subject an effective amount of a gamma-emitting transition metal complex conjugated to a targeting moiety that selectively binds to prostate-specific membrane antigen (PSMA), including PSMA expressed on the surface of a prostate tumor; subjecting the subject to a nuclear medicine tomographic imaging technique to obtain one or more images of at least a portion of prostate tissue that comprises tumor lesions; assessing a level of uptake of said gamma-emitting transition metal complex conjugated to a targeting moiety by said at least a portion of prostate tissue compared to a level of uptake by control tissue; and determining if a ratio of the level of uptake by said at least a portion of prostate tissue compared the level of uptake by control tissue is at or above a predetermined threshold. | 2015-04-23 |
20150110717 | METHODS OF INCREASING THE NUMBER OF TARGET CELLS RECOVERED FROM A FLUID SAMPLE - Methods and materials for increasing the number of target cells recovered from a fluid sample containing cells are described. The methods include isolating the target cells on a filter and then implanting the filter containing the target cells in an immunodeficient non-human animal, where at least some of the target cells can proliferate. | 2015-04-23 |
20150110718 | METHODS AND KITS FOR DETERMINING A PLACEBO PROFILE IN SUBJECTS FOR CLINICAL TRIALS AND FOR TREATMENT OF PATIENTS - The present invention is directed to methods and assays for identifying subjects participating in clinical trials that may exhibit a placebo response and identifying treatments for subjects with varying degrees of placebo responses. In one aspect, a method of selecting subjects to participate in a clinical trial is disclosed. In another aspect, methods for treating a subject and determining a treatment dosage are disclosed. In an exemplary embodiment, a method for determining a response to a treatment of a subject having, suspected of having, or at risk for developing a disorder, such as cardiovascular disorder, irritable bowel syndrome, diabetes, autoimmune disorders, inflammation, neurological disorders, chronic pain, cancer, cancer treatments, allergies, depression, migraines, addiction, obesity, and other disorders, syndromes, or diseases, is disclosed. | 2015-04-23 |
20150110719 | HYDROGEL BASED DELIVERY AND SENSOR - Described are catheters associated with a hydrogel for release of a molecule of interest. The molecule of interest may be an antibody. Further described are sensors useful for detecting the presence or amount of an analyte, and associated methods. A sensor for use in detecting the presence or amount of an analyte may comprise a catheter having one or more apertures. The sensor may also include means for detecting binding of the analyte to an antibody. | 2015-04-23 |
20150110720 | FLUORESCENT FUSION POLYPEPTIDES AND METHODS OF USE - Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus. | 2015-04-23 |
20150110721 | Modulation of a Response Signal to Distinguish Between Analyte and Background Signals - A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal. | 2015-04-23 |
20150110722 | IMAGEABLE POLYMERS - The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalised with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system. | 2015-04-23 |
20150110723 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO - The disclosure relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidases (Nox enzymes) and/or myeloperoxidase. | 2015-04-23 |
20150110724 | High SPF Transparent or Translucent Naturally Derived, Cytoprotective, UV Radiation Resistant Compositions - A composition comprising (a) at least one inorganic sun-block or sunscreen agent that is a proven non-endocrine disrupter, (b) at least one emollient or mixtures thereof proven to be a non-endocrine disrupter; (c) at least one emulsifier; and (d) an oil component capable of boosting SPF values. The compositions of the present invention are shown to be capable of protecting skin and mammalian health from the harmful effects of radiation including ultraviolet light or sunlight by inhibiting the loss of skin immuno-competency and eliminating any known or suspected endocrine disrupting agents normally utilized as sun protective agents. Test methodology and results indicate dramatic differences from commercially available formulations. | 2015-04-23 |
20150110725 | MIXTURE FOR THE INHIBITION OF MELANIN BIOSYNTHESIS - The present invention relates to a mixture comprising acetylglucosamine and 4-(1-phenylethyl)-1,3-benzenediol for use as a cosmetic and/or medicament, and particularly for the inhibition of melanin biosynthesis, and to a cosmetic and/or pharmaceutical formulation comprising such a mixture for the treatment of hyperpigmented lesions of the skin such as, for example but without limitation, lentigo solaris, age spots, melasma and chloasma, for rendering uniform the color of the skin, for counteracting the formation of free radicals, and for counteracting or preventing signs of skin aging such as wrinkles and lack of skin tone, and generally for improving the aesthetic conditions of the skin. | 2015-04-23 |
20150110726 | USES OF COMPOUNDS AND MIXTURES FROM ANTRODIA CINNAMOMEA MYCELIA - The present invention relates to novel uses of compounds from | 2015-04-23 |
20150110727 | 3-(CYCLOHEX-1-EN-1-YL)PROPIONATES AND THEIR USE IN PERFUME COMPOSITIONS - The present invention pertains to novel 3-(cyclohex-1-en-1-yl)propionates, the unexpected advantageous use thereof in enhancing, improving or modifying the fragrance of perfumes, colognes, toilet waters, fabric care products, personal products, and the like, and the unexpected advantageous use thereof in counteracting malodors. | 2015-04-23 |
20150110728 | PERSONAL CARE COMPOSITION - Disclosed is a personal care composition comprising cooling active and copolymer comprising acrylamidopropyltrimonium chloride, wherein the weight ratio of the amount of the cooling active to the amount of the copolymer is in the range from 1:5 to 100:1. The copolymer improves deposition of the cooling active during topical application of the product to skin. | 2015-04-23 |
20150110729 | PRODUCT FOR TEMPORARILY SHAPING KERATIN FIBERS ON THE BASIS OF A COMBINATION OF SPECIFIC FILM-FORMING POLYMERS - Cosmetic agents, containing in a cosmetically acceptable carrier a) at least one copolymer A of 2-acrylamido-2-methylpropanesulfonic acid with one or more monomers selected from acrylic acid and methacrylic acid, b) at least one polymeric quaternary ammonium compound from the group of vinylpyrrolidone copolymers B, are particularly suitable for temporarily deforming keratinic fibers. | 2015-04-23 |
20150110730 | Volumizing Hair Compositions Containing Styling Polymers and Polycationic Polymers - Rinse-off of the volumizing compositions, having an acidic pH, and in the form of a lotion, gel or cream are disclosed. The compositions include one or more linear hairstyling polymers which exhibit polar behavior in acidic pH, such as polyvinylpyrrolidone, together with a selected group of polycationic hairstyling polymers, such as polyquaternium-37. The compositions not only provide a strong hair volumizing effect, but that effect is durable, being retained after two or more shampooing operations of the hair. The compositions are used by applying an effective amount to wet hair, leaving the composition for at least about three minutes, and rinsing the composition out of the hair. | 2015-04-23 |
20150110731 | Inhibitor of Odor Caused by Furaneol - Provided is a substance inhibiting an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone. An inhibitor of an odor caused by 2,5-dimethyl-4-hydroxy-3(2H)-furanone, comprising a substance inhibiting the response of an olfactory receptor OR5K1 as an active ingredient. | 2015-04-23 |
20150110732 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness. | 2015-04-23 |
20150110733 | GENETIC MARKERS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE - The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of:
| 2015-04-23 |
20150110734 | TRAIL SINGLE CHAIN MOLECULES - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 2015-04-23 |
20150110735 | HIGH-SPEED CENTRIFUGAL MIXING DEVICES AND METHODS OF USE - A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction. | 2015-04-23 |
20150110736 | METHODS FOR DETERMINING THE EFFECTS OF COMPOUNDS ON JAK/STAT ACTIVITY - An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds. | 2015-04-23 |
20150110737 | METHODS OF PRODUCING AND USING REGULATORY B-CELLS - The invention is directed to a method of preparing B-cells that produce interleukin-10 (IL-10), or IL-10 per se, which comprises contacting one or more B-cells ex vivo with an isolated interleukin-35 (IL-35) protein, and culturing the one or more B-cells under conditions to provide one or more B-cells that produce IL-10. The invention also is directed to a method of suppressing the proliferation of lymphocytes in vitro or in vivo by contacting lymphocytes with an isolated IL-35 protein. The invention further is directed to a method of suppressing autoimmunity in a mammal by administering to the mammal an IL-35 protein or IL-10-producing B-cells. | 2015-04-23 |
20150110738 | METHODS AND COMPOSITIONS FOR GENERATING AND USING ALLOGENEIC SUPPRESSOR CELLS - The present invention is directed to generating suppressor cells by treating naive T cells with a suppressor-inducing composition such as anti-CD3, anti-CD28, IL-2, TGF-β, or some combination thereof. Such suppressor cells are administered to patients to prevent or treat immune disorders and are allogeneic to the patient. | 2015-04-23 |
20150110739 | USES OF IL-12 AND THE IL-12 RECEPTOR POSITIVE CELL IN TISSUE REPAIR AND REGENERATION - The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells. | 2015-04-23 |
20150110740 | CARRIER-FREE BIOLOGICALLY-ACTIVE PROTEIN NANOSTRUCTURES - The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell. | 2015-04-23 |
20150110741 | COGNITIVE COMPOSITE PARAMETERS AND USES THEREOF FOR EVALUATING MULTIPLE SCLEROSIS - Methods, systems and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis are disclosed. | 2015-04-23 |
20150110742 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule. | 2015-04-23 |
20150110743 | LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin. | 2015-04-23 |
20150110744 | PEPTIDE AGENTS FOR CANCER THERAPY - There is provided peptides for inhibiting growth of cancer cells, the peptides comprising the amino acid sequence RxKxKxxxxR wherein K and R are respectively lysine and arginine amino acid residues, each x is independently an amino acid, and 5 wherein the peptide has 50% or less amino acid sequence identity with the amino acid sequence RSKAKNPLYR (SEQ ID. No. 2). Each x amino acid may independently be an amino acid residue selected from the group consisting of alanine (A), valine (V), leucine (L), isoleucine (I), threonine (T) and serine (S) amino acid residues. There is also provided chimeric proteins incorporating a peptide of the amino acid sequence 10 RxKxKxxxxR, nucleic acids encoding for the peptide, expression vectors including a nucleic acid encoding the peptide for expression of the peptide, and methods for use of the peptide for inhibiting growth of cancer cells. | 2015-04-23 |
20150110745 | FILAMENTOUS BACTERIOPHAGE AS AN ANGIOGENESIS MODULATOR - The invention relates to a filamentous bacteriophage, carrying bacterial Lipopolysaccharide (LPS) endotoxin on its surface, for use in treating cancer and in inhibiting angiogenesis, and in a different context, for use in promoting angiogenesis in diseases or conditions in which there is insufficient angiogenesis. | 2015-04-23 |
20150110746 | PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS - The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. | 2015-04-23 |
20150110747 | Bone Grafts Including Osteogenic Stem Cells, and Methods Relating to the Same - Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof. | 2015-04-23 |
20150110748 | Bone Grafts Including Osteogenic Stem Cells, and Methods Relating to the Same - Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof. | 2015-04-23 |
20150110749 | GENERATING PLURIPOTENT CELLS DE NOVO - The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material. | 2015-04-23 |
20150110750 | METHODS FOR USING AUTOLOGOUS FIBROBLASTS TO ALTER SKIN IDENTITY - The present invention relates to the field of autologous fibroblasts. More specifically, the present invention provides methods and compositions comprising autologous fibroblasts and uses thereof to alter skin identity. In certain embodiments, volar fibroblasts can be expanded for the ability to induce volar skin at the stump site in amputees. In other embodiments, fibroblasts from haired scalp can be expanded to ameliorate alopecias. | 2015-04-23 |
20150110751 | STEM CELLS AS AN INDIVIDUALIZED MATERNAL THERAPY FOR PREVENTION OF PREMATURITY - The present invention relates to the field of premature birth. More specifically, the present invention provides methods and compositions useful for preventing premature birth. In one embodiment, a method for preventing preterm birth in a patient comprises the step of administering to the patient an effective amount of autologous mesenchymal stem cells (MSCs) during the first or second trimester. | 2015-04-23 |
20150110752 | MAGNETIC EXTRACELLULAR MATRIX - Methods of making and using a magnetic ECM are disclosed. The ECM comprises positively and negatively charged nanoparticles, wherein one of said nanoparticles contains a magnetically responsive element. When the magnetic ECM is seeded with cells, the cells will be magnetized and can be levitated for 3-D cell culture. | 2015-04-23 |
20150110753 | BIOMATRIX SCAFFOLDS - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same. | 2015-04-23 |
20150110754 | High Resolution Allele Identification - Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology. | 2015-04-23 |
20150110755 | ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME - The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention. | 2015-04-23 |
20150110756 | THREE-DIMENSIONAL TISSUE STRUCTURE - The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult. | 2015-04-23 |
20150110757 | MODIFICATION OF CXCR4 USING ENGINEERED ZINC FINGER PROTEINS - Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided. | 2015-04-23 |
20150110758 | TREATMENT OF NEUROCUTANEOUS SYNDROME, INCLUDING COMPOSITIONS, METHODS AND USES THEREOF - A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof. | 2015-04-23 |
20150110759 | COMPOSITIONS AND METHODS FOR MICROBE STORAGE AND DELIVERY - The present invention relates to the field of bacteriology. In particular, the invention relates to compositions of probiotic microbes and methods for making and using such compositions, e.g. in the treatment and prevention of catheter associated urinary tract infections. | 2015-04-23 |
20150110760 | NKP30 RECEPTOR TARGETED THERAPEUTICS - The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same. | 2015-04-23 |
20150110761 | EXPANSION OF ALLOANTIGEN-REACTIVE REGULATORY T CELLS - The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants. | 2015-04-23 |
20150110762 | DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING - The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell. | 2015-04-23 |
20150110763 | Cell Washing Device Using A Wave - A system is disclosed for washing a selected component and removing the selected component from a wash material. The selected component may include red blood cells that are washed to remove a rejuvenating solution. The red blood cells may then be removed with various systems, such as a standing acoustic wave system from the wash solution. Pumps and flow restrictors that provide steady flow from pumps that generate pulsed flow are also disclosed. | 2015-04-23 |
20150110764 | Food-Induced Antisecretory Proteins - The use of products having enzymatic activity for the preparation of a food, including feed, inducing, when consumed, antisecretory proteins and the foods thus prepared. The products having enzymatic activity may for example be malted cereals. | 2015-04-23 |
20150110765 | Polypeptides Having Alpha-Glucuronidase Activity And Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having alpha-glucuronidase activity, catalytic domains and polynucleotides encoding the polypeptides, catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides or catalytic domains. | 2015-04-23 |
20150110766 | REGULATOR OF COMPLEMENT ACTIVATION AND USES THEREOF - A potent complement regulator is disclosed. The complement regulator comprises a complement regulatory region connected by a flexible linker to a multifunctional binding region that enables binding to C3b activation/inactivation products and/or oxidation end products, as well as to polyanionic surface markers on host cells. An embodiment of the invention utilizes factor H SCRs 1-4 as the complement regulatory region and factor H SCRs 19 and 20 as the multi-functional binding region, linked together by a poly-Gly linker at least 12 residues in length. Pharmaceutical compositions comprising the complement regulator and methods of using the complement regulator are also disclosed. | 2015-04-23 |
20150110767 | METHODS FOR TREATING LUNG INFECTIONS AND INFLAMMATION - Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described. | 2015-04-23 |
20150110768 | COMPOSITIONS AND METHODS COMPRISING SIRTUIN STIMULATORS AND NON-SIRTUIN PROTEIN DEACETYLASE INHIBITORS - The present technology relates to cosmetic and pharmaceutical compositions useful for minimizing the appearance of aging via a safe method of stimulating sirtuin activity. In particular, the present technology relates to compositions and methods that utilize a combination of a sirtuin activator with a sirtuin-offsetting agent in order to maintain a healthy population of skin cells while preventing survival and growth of abnormal cells that are irreparably damaged. | 2015-04-23 |
20150110769 | METHOD FOR RETARDING UNHEALTHY MANIFESTATIONS BROUGHT BY AGEING OF HUMAN BEINGS - The present invention provides a method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis). According to the invention this task is solved by administration into the blood circulation of an agent which inactivates extracellular blood plasma DNA e.g. a DNase enzyme. | 2015-04-23 |
20150110770 | Crotoxin Administration for Cancer Treatment - A method for treating cancer using an intra-patient dose escalation procedure to deliver dosages of | 2015-04-23 |
20150110771 | ENZYMES AND METHODS FOR CLEAVING N-GLYCANS FROM GLYCOPROTEINS - Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity. | 2015-04-23 |
20150110772 | CUCURBITURIL-BASED HYDROGELS - The invention provides hydrogel, wherein the hydrogel has a supramolecular cross-linked network obtainable or obtained from the complexation of an aqueous composition including a host, such as cucurbituril, and one or more polymers having suitable guest functionality. One or more polymers in the aqueous composition may have a molecular weight of 50 kDa or more, such as 200 kDa or more. The hydrogel may hold a component, such as a therapeutic compound or a biological molecule. The hydrogels are suitable for use in medicine. | 2015-04-23 |
20150110773 | TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER - Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided. | 2015-04-23 |
20150110774 | S100 PROTEIN INHIBITORS FOR TREATING LEUKEMIA - The present invention relates to a compound, composition and method for reducing or inhibiting the differentiation or development of progenitor blood cells into malignant cells, leukemia cells or physiologically pathological cells. Particularly, the invention describes the use of inhibitors of S100 proteins, including myeloid related proteins. Inhibition of the activity or synthesis of S100 proteins results into reduction or inhibition of the production or proliferation of aberrant and cancer blood cells. | 2015-04-23 |
20150110775 | MODULATED LYSINE VARIANT SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME - The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα is detrimental, are also provided. | 2015-04-23 |
20150110776 | ANTIBODIES THAT RECOGNIZE IAPP - The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions. | 2015-04-23 |
20150110777 | ANTIBODIES THAT RECOGNIZE IAPP - The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions. | 2015-04-23 |
20150110778 | COMPOSITIONS COMPRISING MG53 AND METHODS FOR THE TREATMENT AND PREVENTION OF AIRWAY INJURY - Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof. | 2015-04-23 |
20150110779 | METHODS FOR PREDICTING GASTROINTESTINAL IMMUNE-RELATED ADVERSE EVENTS (GI-IRAE) IN PATIENTS TREATED WITH MODULATION OF THE CO-STIMULATORY PATHWAY - The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system. | 2015-04-23 |
20150110780 | TREATMENT OF BRAIN CANCER - Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein. | 2015-04-23 |
20150110781 | COMPOSITIONS AND METHODS RELATED TO THE PREVENTION AND TREATMENT OF RABIES INFECTION - The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection. | 2015-04-23 |
20150110782 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are | 2015-04-23 |
20150110783 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS - Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component. | 2015-04-23 |
20150110784 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS - The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component. | 2015-04-23 |
20150110785 | Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15 - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes. | 2015-04-23 |
20150110786 | COMPOSITIONS FOR INHIBITION OF QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME - A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane. | 2015-04-23 |
20150110787 | POLYPEPTIDE SPECIFICALLY BINDING TO VEGF-C AND USE THEREOF - A polypeptide, antagonist, and antibody that specifically bind to and inhibit VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample. | 2015-04-23 |
20150110788 | BISPECIFIC ANTIBODIES WITH AN FGF2 BINDING DOMAIN - The present invention provides a bispecific antibody having a binding domain that binds to FGF2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2015-04-23 |
20150110789 | Bispecific SCFV Immunofusion (BIF) - Certain embodiments are directed to a bispecific immunoglobulin that is capable of binding cell surface molecules on a target cell, such as cancer cells, and cell surface molecules on immune effector cell, such as cytotoxic T lymphocytes, resulting in the targeted killing of target cells. In certain aspects a Bif is a polypeptide comprising a first target binding domain that specifically binds a cancer cell, a second effector binding domain that specifically binds an immunologic effector, and an immunoglobulin constant region linker operatively coupling the first and second binding domain. | 2015-04-23 |
20150110790 | COMPOSITION FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES - A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment. | 2015-04-23 |